Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company, announced its participation in two upcoming investor conferences in September 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company, announced its participation in two upcoming investor conferences in September 2024. The company will attend the Wells Fargo Healthcare Conference on September 4 for one-on-one meetings. At the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, Foghorn's President and CEO, Adrian Gottschalk, will give a presentation at 8:30 a.m. EDT and participate in one-on-one meetings.
Foghorn is pioneering a new class of medicines that correct abnormal gene expression to treat serious diseases, with an initial focus on oncology. Their Gene Traffic Control® platform and broad pipeline aim to transform lives across various diseases. A webcast of the Morgan Stanley presentation will be available on the company's website for 30 days.
Details
News Market Reaction – FHTX
The recorded move for FHTX in the trading session of this news was -4.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 Wells Fargo Healthcare Conference and presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
2024 Wells Fargo Healthcare Conference
- Management will participate in one-on-one meetings on Wednesday, September 4
Morgan Stanley 22nd Annual Global Healthcare Conference
- Presentation: Friday, September 6, 2024, at 8:30 a.m. EDT at the Marriott Marquis, New York, New York
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings on Friday, September 6
A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information about the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.